Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 369

1.

Cancer risk in primary sclerosing cholangitis: Epidemiology, prevention, and surveillance strategies.

Fung BM, Lindor KD, Tabibian JH.

World J Gastroenterol. 2019 Feb 14;25(6):659-671. doi: 10.3748/wjg.v25.i6.659. Review.

2.

NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A nebulous matter.

Tabibian JH, Lindor KD.

J Hepatol. 2019 Mar;70(3):348-350. doi: 10.1016/j.jhep.2018.12.006. Epub 2019 Jan 6. No abstract available.

PMID:
30626486
3.

Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis.

Cheung AC, Lammers WJ, Murillo Perez CF, van Buuren HR, Gulamhusein A, Trivedi PJ, Lazaridis KN, Ponsioen CY, Floreani A, Hirschfield GM, Corpechot C, Mayo MJ, Invernizzi P, Battezzati PM, Parés A, Nevens F, Thorburn D, Mason AL, Carbone M, Kowdley KV, Bruns T, Dalekos GN, Gatselis NK, Verhelst X, Lindor KD, Lleo A, Poupon R, Janssen HL, Hansen BE; Global PBC Study Group.

Clin Gastroenterol Hepatol. 2019 Jan 4. pii: S1542-3565(19)30001-1. doi: 10.1016/j.cgh.2018.12.028. [Epub ahead of print]

PMID:
30616022
4.

Antimitochondrial Antibody-Negative Primary Biliary Cholangitis: Is It Really the Same Disease?

Chascsa DM, Lindor KD.

Clin Liver Dis. 2018 Aug;22(3):589-601. doi: 10.1016/j.cld.2018.03.009. Review.

PMID:
30259855
5.

Primary sclerosing cholangitis in children versus adults: lessons for the clinic.

Adike A, Carey EJ, Lindor KD.

Expert Rev Gastroenterol Hepatol. 2018 Oct;12(10):1025-1032. doi: 10.1080/17474124.2018.1521719. Epub 2018 Oct 1.

PMID:
30199272
6.

Primary Sclerosing Cholangitis, Part 2: Cancer Risk, Prevention, and Surveillance.

Tabibian JH, Ali AH, Lindor KD.

Gastroenterol Hepatol (N Y). 2018 Jul;14(7):427-432.

7.

Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases.

Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M.

Hepatology. 2019 Jan;69(1):394-419. doi: 10.1002/hep.30145. Epub 2018 Nov 6. No abstract available.

PMID:
30070375
8.

Dominant strictures in primary sclerosing cholangitis: A multicenter survey of clinical definitions and practices.

Hilscher MB, Tabibian JH, Carey EJ, Gostout CJ, Lindor KD.

Hepatol Commun. 2018 May 4;2(7):836-844. doi: 10.1002/hep4.1194. eCollection 2018 Jul.

9.

Primary Sclerosing Cholangitis, Part 1: Epidemiology, Etiopathogenesis, Clinical Features, and Treatment.

Tabibian JH, Ali AH, Lindor KD.

Gastroenterol Hepatol (N Y). 2018 May;14(5):293-304.

10.

Managing PBC: Expanding the Provider Comfort Zone.

Chascsa DM, Lindor KD.

Dig Dis Sci. 2018 Oct;63(10):2487-2488. doi: 10.1007/s10620-018-5162-9. No abstract available.

PMID:
29948561
11.

Characteristics and Outcomes Reported by Patients With Primary Sclerosing Cholangitis Through an Online Registry.

Kuo A, Gomel R, Safer R, Lindor KD, Everson GT, Bowlus CL.

Clin Gastroenterol Hepatol. 2018 Apr 26. pii: S1542-3565(18)30409-9. doi: 10.1016/j.cgh.2018.04.047. [Epub ahead of print]

PMID:
29705262
12.

Design and Endpoints for Clinical Trials in Primary Sclerosing Cholangitis.

Ponsioen CY, Lindor KD, Mehta R, Dimick-Santos L.

Hepatology. 2018 Sep;68(3):1174-1188. doi: 10.1002/hep.29882. Epub 2018 Aug 31. Review.

PMID:
29574971
13.

Editorial: is proton pump inhibitor use associated with worse outcomes in patients with liver abscesses?

Tabibian JH, Lindor KD.

Aliment Pharmacol Ther. 2018 Apr;47(8):1226-1227. doi: 10.1111/apt.14568. No abstract available.

PMID:
29574873
14.

Increased Waitlist Mortality and Lower Rate for Liver Transplantation in Hispanic Patients With Primary Biliary Cholangitis.

Cholankeril G, Gonzalez HC, Satapathy SK, Gonzalez SA, Hu M, Khan MA, Yoo ER, Li AA, Kim D, Nair S, Wong RJ, Kwo PY, Harrison SA, Younossi ZM, Lindor KD, Ahmed A.

Clin Gastroenterol Hepatol. 2018 Jun;16(6):965-973.e2. doi: 10.1016/j.cgh.2017.12.017. Epub 2018 Feb 8.

PMID:
29427734
15.

Review article: the evidence that vancomycin is a therapeutic option for primary sclerosing cholangitis.

Damman JL, Rodriguez EA, Ali AH, Buness CW, Cox KL, Carey EJ, Lindor KD.

Aliment Pharmacol Ther. 2018 Apr;47(7):886-895. doi: 10.1111/apt.14540. Epub 2018 Feb 7. Review.

PMID:
29411404
16.

Editorial: Itching to Know: Role of Fibrates in PBC.

Levy C, Lindor KD.

Am J Gastroenterol. 2018 Jan;113(1):56-57. doi: 10.1038/ajg.2017.432.

PMID:
29311728
17.

Surveillance for hepatobiliary cancers in patients with primary sclerosing cholangitis.

Ali AH, Tabibian JH, Nasser-Ghodsi N, Lennon RJ, DeLeon T, Borad MJ, Hilscher M, Silveira MG, Carey EJ, Lindor KD.

Hepatology. 2018 Jun;67(6):2338-2351. doi: 10.1002/hep.29730. Epub 2018 Apr 19.

PMID:
29244227
18.

Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome.

Harms MH, Lammers WJ, Thorburn D, Corpechot C, Invernizzi P, Janssen HLA, Battezzati PM, Nevens F, Lindor KD, Floreani A, Ponsioen CY, Mayo MJ, Dalekos GN, Bruns T, Parés A, Mason AL, Verhelst X, Kowdley KV, Goet JC, Hirschfield GM, Hansen BE, van Buuren HR; Global PBC Study Group.

Am J Gastroenterol. 2018 Feb;113(2):254-264. doi: 10.1038/ajg.2017.440. Epub 2017 Dec 12.

PMID:
29231188
19.

Milder disease stage in patients with primary biliary cholangitis over a 44-year period: A changing natural history.

Murillo Perez CF, Goet JC, Lammers WJ, Gulamhusein A, van Buuren HR, Ponsioen CY, Carbone M, Mason A, Corpechot C, Invernizzi P, Mayo MJ, Battezzati PM, Floreani A, Pares A, Nevens F, Kowdley KV, Bruns T, Dalekos GN, Thorburn D, Hirschfield G, LaRusso NF, Lindor KD, Zachou K, Poupon R, Trivedi PJ, Verhelst X, Janssen HLA, Hansen BE; GLOBAL PBC Study Group.

Hepatology. 2018 May;67(5):1920-1930. doi: 10.1002/hep.29717. Epub 2018 Apr 6.

PMID:
29220537
20.

Curcumin in Hepatobiliary Disease: Pharmacotherapeutic Properties and Emerging Potential Clinical Applications.

Hu RW, Carey EJ, Lindor KD, Tabibian JH.

Ann Hepatol. 2017 November-December,;16(6):835-841. doi: 10.5604/01.3001.0010.5273. Review.

21.

Heterogeneity of Outcomes Following Liver Transplantation for Primary Sclerosing Cholangitis: Age Matters.

Martin P, Lindor KD.

Dig Dis Sci. 2017 Nov;62(11):3210-3211. doi: 10.1007/s10620-017-4758-9. No abstract available.

PMID:
28965148
22.

Complications, symptoms, quality of life and pregnancy in cholestatic liver disease.

Zakharia K, Tabibian A, Lindor KD, Tabibian JH.

Liver Int. 2018 Mar;38(3):399-411. doi: 10.1111/liv.13591. Epub 2017 Oct 3. Review.

PMID:
28921801
23.

Investigational drugs in phase II clinical trials for primary biliary cholangitis.

Silveira MG, Lindor KD.

Expert Opin Investig Drugs. 2017 Oct;26(10):1115-1121. doi: 10.1080/13543784.2017.1371135. Epub 2017 Aug 31. Review.

PMID:
28836457
24.

Advances in primary sclerosing cholangitis.

Horsley-Silva JL, Carey EJ, Lindor KD.

Lancet Gastroenterol Hepatol. 2016 Sep;1(1):68-77. doi: 10.1016/S2468-1253(16)30010-3. Epub 2016 Aug 10. Review.

PMID:
28404115
25.

Old and new treatments for primary biliary cholangitis.

Chascsa D, Carey EJ, Lindor KD.

Liver Int. 2017 Apr;37(4):490-499. doi: 10.1111/liv.13294. Review.

PMID:
28371104
26.

Emerging treatments for primary sclerosing cholangitis.

Rodriguez EA, Carey EJ, Lindor KD.

Expert Rev Gastroenterol Hepatol. 2017 May;11(5):451-459. doi: 10.1080/17474124.2017.1293524. Epub 2017 Feb 22. Review.

PMID:
28276816
27.

Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis.

Weismüller TJ, Trivedi PJ, Bergquist A, Imam M, Lenzen H, Ponsioen CY, Holm K, Gotthardt D, Färkkilä MA, Marschall HU, Thorburn D, Weersma RK, Fevery J, Mueller T, Chazouillères O, Schulze K, Lazaridis KN, Almer S, Pereira SP, Levy C, Mason A, Naess S, Bowlus CL, Floreani A, Halilbasic E, Yimam KK, Milkiewicz P, Beuers U, Huynh DK, Pares A, Manser CN, Dalekos GN, Eksteen B, Invernizzi P, Berg CP, Kirchner GI, Sarrazin C, Zimmer V, Fabris L, Braun F, Marzioni M, Juran BD, Said K, Rupp C, Jokelainen K, Benito de Valle M, Saffioti F, Cheung A, Trauner M, Schramm C, Chapman RW, Karlsen TH, Schrumpf E, Strassburg CP, Manns MP, Lindor KD, Hirschfield GM, Hansen BE, Boberg KM; International PSC Study Group.

Gastroenterology. 2017 Jun;152(8):1975-1984.e8. doi: 10.1053/j.gastro.2017.02.038. Epub 2017 Mar 6.

28.

An update on cancer risk and surveillance in primary sclerosing cholangitis.

Horsley-Silva JL, Rodriguez EA, Franco DL, Lindor KD.

Liver Int. 2017 Aug;37(8):1103-1109. doi: 10.1111/liv.13354. Epub 2017 Jan 28. Review.

PMID:
28028930
29.

The Microbiome and Primary Sclerosing Cholangitis.

Ali AH, Carey EJ, Lindor KD.

Semin Liver Dis. 2016 Sep;36(4):340-348. doi: 10.1055/s-0036-1594007. Epub 2016 Dec 20. Review.

PMID:
27997974
30.

Update on pharmacotherapies for cholestatic liver disease.

Ali AH, Tabibian JH, Lindor KD.

Hepatol Commun. 2016 Dec 21;1(1):7-17. doi: 10.1002/hep4.1013. eCollection 2017 Feb. Review.

31.

Obeticholic Acid in Primary Biliary Cholangitis.

Nevens F, Lindor KD, Jones DE.

N Engl J Med. 2016 Nov 17;375(20):e41. doi: 10.1056/NEJMc1611913. No abstract available.

PMID:
27959605
32.

Clinical implications of serial versus isolated biliary fluorescence in situ hybridization (FISH) polysomy in primary sclerosing cholangitis.

Quinn KP, Tabibian JH, Lindor KD.

Scand J Gastroenterol. 2017 Apr;52(4):377-381. doi: 10.1080/00365521.2016.1263681. Epub 2016 Dec 1.

PMID:
27908204
33.

Oral Vancomycin Therapy in a Child with Primary Sclerosing Cholangitis and Severe Ulcerative Colitis.

Buness C, Lindor KD, Miloh T.

Pediatr Gastroenterol Hepatol Nutr. 2016 Sep;19(3):210-213. Epub 2016 Sep 29.

34.

Shifting Paradigms: What Is the True Prevalence and Clinical Course of Primary Sclerosing Cholangitis?

Weersma RK, Lindor KD.

Gastroenterology. 2016 Oct;151(4):590-3. doi: 10.1053/j.gastro.2016.08.046. Epub 2016 Aug 30. No abstract available.

PMID:
27590692
35.

A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis.

Nevens F, Andreone P, Mazzella G, Strasser SI, Bowlus C, Invernizzi P, Drenth JP, Pockros PJ, Regula J, Beuers U, Trauner M, Jones DE, Floreani A, Hohenester S, Luketic V, Shiffman M, van Erpecum KJ, Vargas V, Vincent C, Hirschfield GM, Shah H, Hansen B, Lindor KD, Marschall HU, Kowdley KV, Hooshmand-Rad R, Marmon T, Sheeron S, Pencek R, MacConell L, Pruzanski M, Shapiro D; POISE Study Group.

N Engl J Med. 2016 Aug 18;375(7):631-43. doi: 10.1056/NEJMoa1509840.

36.

Obeticholic acid for the treatment of primary biliary cholangitis.

Ali AH, Lindor KD.

Expert Opin Pharmacother. 2016 Sep;17(13):1809-15. doi: 10.1080/14656566.2016.1218471. Epub 2016 Aug 9. Review.

PMID:
27468093
37.

Combination Therapy of All-Trans Retinoic Acid With Ursodeoxycholic Acid in Patients With Primary Sclerosing Cholangitis: A Human Pilot Study.

Assis DN, Abdelghany O, Cai SY, Gossard AA, Eaton JE, Keach JC, Deng Y, Setchell KD, Ciarleglio M, Lindor KD, Boyer JL.

J Clin Gastroenterol. 2017 Feb;51(2):e11-e16. doi: 10.1097/MCG.0000000000000591.

38.

A Randomized, Placebo-Controlled Clinical Trial of Efficacy and Safety: Modafinil in the Treatment of Fatigue in Patients With Primary Biliary Cirrhosis.

Silveira MG, Gossard AA, Stahler AC, Jorgensen RA, Petz JL, Ali AH, Lindor KD.

Am J Ther. 2017 Mar/Apr;24(2):e167-e176. doi: 10.1097/MJT.0000000000000387.

PMID:
27148676
39.

Distinguishing immunoglobulin G4-related disease from its pancreatobiliary mimics: Are we there now?

Tabibian JH, Lindor KD.

Hepatology. 2016 Aug;64(2):340-3. doi: 10.1002/hep.28624. Epub 2016 Jun 8. No abstract available.

PMID:
27120155
40.

Reliability and validity of the Chronic Liver Disease Questionnaire (CLDQ) in adults with non-alcoholic steatohepatitis (NASH).

Chawla KS, Talwalkar JA, Keach JC, Malinchoc M, Lindor KD, Jorgensen R.

BMJ Open Gastroenterol. 2016 Mar 16;3(1):e000069. doi: 10.1136/bmjgast-2015-000069. eCollection 2016.

41.

Emerging drugs for the treatment of Primary Biliary Cholangitis.

Ali AH, Tabibian JH, Carey EJ, Lindor KD.

Expert Opin Emerg Drugs. 2016;21(1):39-56. Review.

PMID:
26901615
42.

 Alkaline phosphatase normalization is a biomarker of improved survival in primary sclerosing cholangitis.

Hilscher M, Enders FB, Carey EJ, Lindor KD, Tabibian JH.

Ann Hepatol. 2016 Mar-Apr;15(2):246-53. doi: 10.5604/16652681.1193721.

PMID:
26845602
43.

Long-term outcomes in antimitochondrial antibody negative primary biliary cirrhosis.

Juliusson G, Imam M, Björnsson ES, Talwalkar JA, Lindor KD.

Scand J Gastroenterol. 2016;51(6):745-52. doi: 10.3109/00365521.2015.1132337. Epub 2016 Jan 18.

PMID:
26776319
44.

The management of autoimmunity in patients with cholestatic liver diseases.

Ali AH, Carey EJ, Lindor KD.

Expert Rev Gastroenterol Hepatol. 2016;10(1):73-91. doi: 10.1586/17474124.2016.1095088. Epub 2015 Nov 2. Review.

PMID:
26523975
45.

Docetaxel Induced Sclerosing Cholangitis.

Horsley-Silva JL, Dow EN, Menias CO, Smith ML, Carballido EM, Lindor KD, Vargas HE.

Dig Dis Sci. 2015 Dec;60(12):3814-6. No abstract available.

PMID:
26501143
46.

Primary biliary cirrhosis.

Carey EJ, Ali AH, Lindor KD.

Lancet. 2015 Oct 17;386(10003):1565-75. doi: 10.1016/S0140-6736(15)00154-3. Epub 2015 Sep 11. Review. Erratum in: Lancet. 2015 Oct 17;386(10003):1536.

PMID:
26364546
47.

Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy.

Lammers WJ, Hirschfield GM, Corpechot C, Nevens F, Lindor KD, Janssen HL, Floreani A, Ponsioen CY, Mayo MJ, Invernizzi P, Battezzati PM, Parés A, Burroughs AK, Mason AL, Kowdley KV, Kumagi T, Harms MH, Trivedi PJ, Poupon R, Cheung A, Lleo A, Caballeria L, Hansen BE, van Buuren HR; Global PBC Study Group.

Gastroenterology. 2015 Dec;149(7):1804-1812.e4. doi: 10.1053/j.gastro.2015.07.061. Epub 2015 Aug 7.

PMID:
26261009
48.

Primary biliary cirrhosis: safety and benefits of established and emerging therapies.

Tabibian JH, Lindor KD.

Expert Opin Drug Saf. 2015;14(9):1435-44. doi: 10.1517/14740338.2015.1073260. Epub 2015 Jul 28. Review.

PMID:
26212223
49.

ACG Clinical Guideline: Primary Sclerosing Cholangitis.

Lindor KD, Kowdley KV, Harrison ME; American College of Gastroenterology.

Am J Gastroenterol. 2015 May;110(5):646-59; quiz 660. doi: 10.1038/ajg.2015.112. Epub 2015 Apr 14.

PMID:
25869391
50.

Recent advances in the development of farnesoid X receptor agonists.

Ali AH, Carey EJ, Lindor KD.

Ann Transl Med. 2015 Jan;3(1):5. doi: 10.3978/j.issn.2305-5839.2014.12.06. Review.

Supplemental Content

Loading ...
Support Center